MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Marinus Pharmaceuticals, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors during the specified class period [1][2]. Group 1: Legal Investigation - The investigation is focused on whether Marinus' board of directors made materially false and misleading statements regarding the company's business and operations [2]. - The class action complaint was filed on June 5, 2024, covering a class period from March 17, 2021, to May 7, 2024 [1]. - Allegations include the understatement of risks related to the RAISE trial and the failure to disclose potential consequences of not meeting early-stopping criteria [2]. Group 2: Contact Information - Long-term stockholders of Marinus are encouraged to contact Bragar Eagel & Squire for more information regarding their legal rights and the ongoing investigation [3][6]. - Contact can be made via email or telephone, with no cost or obligation to the stockholders [3].